# Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME)

> **NCT03003416** · — · COMPLETED · sponsor: **Allergan** · enrollment: 115 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** dexamethasone intravitreal implant

## Key facts

- **NCT ID:** NCT03003416
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-19
- **Primary completion:** 2018-12-19
- **Final completion:** 2018-12-19
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2019-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03003416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03003416, "Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03003416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*